By
Drug Target Review2025-08-18T14:30:02
Researchers at UNSW Sydney have unveiled a next-generation CRISPR tool that could lead to safer treatments for genetic disorders, including Sickle Cell.
Already a member? Sign in
By highlighting cutting-edge research and its practical applications, Drug Target Review enables readers to make decisions that accelerate innovation, translate discoveries into therapies, and create tangible benefits for patients worldwide.
By becoming a member you join a connected and collaborative community driving the industry forward. Member benefits include:
2026-05-12T09:31:00
Contributor Sugish Pillai, Axel Ziemke and Dr Gary Kusdian
2026-05-05T13:24:00
Sponsored by HUB Organoids
2026-05-19T09:46:00
Contributor Dr Nitza Thomasson
2025-10-08T14:00:00
Sponsored by Eurofins Discovery
2024-01-10T08:23:16
Sponsored by BellBrook Labs
2023-03-07T10:55:58
Sponsored by Agilent
Site powered by Webvision Cloud